Avrobio posts 22-month update on Fabry gene therapy trial

Avrobio has provided interim data from a phase 2 trial of its Fabry disease gene therapy AVR-RD-01. The update shows the positive effects on biomarkers seen early in the trial have now persisted for up to 22 months, leading Avrobio to talk up the durability of its one-time treatment.